Jos H Beijnen

发表

Universal access to quality medicines: prioritisation of a-priori solutions.

Raffaella Ravinetto, Thomas P C Dorlo, Marleen Boelaert, 2012, The Lancet. Infectious diseases.

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling

Marie-Christine W. Gast, Jos H Beijnen, Marie-Christine W Gast, 2008, BMC Medical Genomics.

The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry.

Jos H Beijnen, E. J. Rook, H. Rosing, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Jos H Beijnen, J. Schellens, J. Beijnen, 2006, World journal of gastroenterology.

An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

Jos H Beijnen, Irma Meijerman, J. Schellens, 2003, Toxicology and applied pharmacology.

Intoxication with Trazodone Caused by Dirty Facsimile Machine

Jos H Beijnen, J. Beijnen, Linda R Tulner, 2009, Journal of the American Geriatrics Society.

Clinical experience with aurora kinase inhibitors: a review.

Jos H Beijnen, David S Boss, J. Schellens, 2009, The oncologist.

P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib

Jos H Beijnen, J. Beijnen, A. Schinkel, 2012, Journal of Pharmacology and Experimental Therapeutics.

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.

Auke Bult, Jos H Beijnen, J. Beijnen, 2003, Journal of pharmaceutical and biomedical analysis.

Long term stability of lyophilized plasmid DNA pDERMATT.

Jos H Beijnen, J. Beijnen, B. Nuijen, 2013, International journal of pharmaceutics.

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

Jos H Beijnen, J. Beijnen, N. Zelcer, 2002, AIDS.

Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.

Jos H Beijnen, David S Boss, C. Damen, 2009, Analytical biochemistry.

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

Willem Boogerd, Jos H Beijnen, J. Beijnen, 2004, Cancer treatment reviews.

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.

Jos H Beijnen, Irene van den Broek, J. Schellens, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

Jos H Beijnen, Alwin D R Huitema, S. Rodenhuis, 2008, Pharmacogenetics and genomics.

Concise drug review: azacitidine and decitabine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2013, The oncologist.

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

Willem Boogerd, Jos H Beijnen, J. Beijnen, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone

Jos H Beijnen, J. Beijnen, A. Schinkel, 2009, Drug Metabolism and Disposition.

The biological and clinical role of drug transporters at the intestinal barrier.

Jos H Beijnen, J. Schellens, J. Beijnen, 2009, Cancer treatment reviews.

Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

Diederick E Grobbee, Marie-Christine W. Gast, Jos H Beijnen, 2011, BMC Cancer.

Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.

Jos H Beijnen, C. Damen, J. Schellens, 2009, Human antibodies.

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

Ji-Ying Song, Jos H Beijnen, H. Rosing, 2007, The Journal of clinical investigation.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Jos H Beijnen, J. Beijnen, M. Verbeek, 2008, Current clinical pharmacology.

Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.

Jos H Beijnen, Wim van den Brink, Alwin D R Huitema, 2006, Current clinical pharmacology.

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Ton N Schumacher, Jos H Beijnen, Wolfgang Uckert, 2014, Human gene therapy methods.

Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.

Marie-Christine W. Gast, Jos H Beijnen, Marie-Christine W Gast, 2006, Trends in pharmacological sciences.

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Jos H Beijnen, Alwin D R Huitema, S. Rodenhuis, 2009, British journal of clinical pharmacology.

Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

Jos H Beijnen, H. Rosing, J. Beijnen, 2012, International journal of cancer.

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2003, Cancer research.

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

Jos H Beijnen, J. Beijnen, A. Schinkel, 2011, Drug Metabolism and Disposition.

P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan

Jos H Beijnen, J. Beijnen, Jin Zhao, 2007, Clinical Cancer Research.

Lapatinib for advanced or metastatic breast cancer.

Henk-Jan Guchelaar, Jos H Beijnen, J. Schellens, 2012, The oncologist.